Heterocyclic aspartyl protease inhibitors
Disclosed are compounds of the formula Ior a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein    Also disclosed is the method of inhibiting aspartyl protease, and in particular, the methods of treating cardiovascular diseases, cognitive and neurodegenerative diseases, and the methods of inhibiting of Human Immunodeficiency Virus, plasmepins, cathepsin D and protozoal enzymes.Also disclosed are methods of treating cognitive or neurodegenerative diseases using the compounds of formula I in combination with a cholinesterase inhibitor or a muscarinic m1 agonist or m2 antagonist.
Schering Corporation Pharmacopeia, LLC
A C A A C C A C C A A C A C A A C A C C A A A C
A61P C07D A61P A61P C07D C07D A61P C07D C07D A61K A61P C07D A61P C07D A61P A61P C07D A61K C07D C07D A61P A61P A61P C07D
inventional inventional inventional inventional inventional inventional inventional inventional inventional additional inventional inventional inventional inventional inventional inventional inventional additional inventional inventional inventional inventional inventional inventional
Andrew Tao Yusheng Kurt W. Jared N. Corey O. Yuanzan C. Huizhong Brian Lingyan Jianping Robert D. Suresh D. Chuanxing Ying Elizabeth M. Johannes H. Yuefei Zhaoning Gaifa William J. Gang Thuy X. E. Xiaoxiang John P. Zhong-Yue Jeffrey A. Rachael C. Dawit Ulrich Guoqing Michelle L. Jingqi
Stamford Guo Wu Saionz Cumming Strickland Ye Gu McKittrick Wang Pan Mazzola Babu Qu Huang Smith Voigt Shao Zhu Lai Greenlee Qian Le Liu Caldwell Sun Misiaszek Hunter Tadesse Iserloh Li Morris Duo